HUPO Brain Proteome Project Uses Bruker Daltonics' Enhanced ProteinScape(TM) Capabilities for Standard Data Reprocessing.

MUNICH, Germany -- New ProteinScape algorithms, features and functionality boost proteomics research results being presented at 4th HUPO World Congress

At the Human Proteome Organization (HUPO) 4th Annual World Congress, Bruker Daltonics, an operating company of Bruker BioSciences Corporation (NASDAQ: BRKR), announces today that the HUPO Brain Proteome Project (BPP) Bioinformatics Committee has decided to include key new features of Bruker Daltonics' ProteinScape(TM) database solution for proteomics project management in HUPO BPP's standard data reprocessing guidelines. These novel capabilities include the pioneering ScoreBooster(TM), Metascore(TM) and ProteinExtractor(TM), which together are expected to further improve the quality and validation of information and knowledge gained from proteomics projects.

ProteinScape generates high quality information via optimization and validation strategies in every step in the mass spectrometry (MS) data interpretation process. Peptide mass fingerprint (PMF) spectra are pre-processed with ScoreBooster, an algorithm that combines the steps of data calibration, removing calibrant signals and protein searches in an iterative manner, resulting in significant improvement of the protein identification rate.

ProteinScape integrates several different search engines including Mascot, Phenyx and Profound to allow cross-validation and consolidation of the identification results through the complementary use of several search engines using the novel MetaScore algorithm to provide enhanced reliability and to increase confidence by intelligent combination of scoring schemes from these different search engines.

The evaluation of proteins based on the peptides identified by these search engines is performed by the unique ProteinExtractor algorithm which generates true non-redundant protein lists from LC-MS/MS search results. ProteinExtractor decreases redundancies in the protein results, reducing manual validation efforts significantly. "These are the key features for our automated approach in analyzing the HUPO BPP pilot study data," stated Dr. Christian Stephan of the BPP Bioinformatics Committee, who conducts brain proteomics research at the Ruhr University Medical Proteomics Center.

The aim of HUPO's Brain Proteome Project (BPP) pilot studies is to derive in-depth knowledge from samples which are analyzed in laboratories worldwide using different separation and MS techniques. The HUPO BPP data were collected, stored and submitted in ProteinScape, the chosen database system for all of BPP's proteomics project management. Importantly, ProteinScape remains fully in compliance with all applicable HUPO Proteomics Standards Initiative (PSI) standards. To produce reliable, reproducible and comparable results, reprocessing of all proteomics data is currently performed with ProteinScape at the Data Collection Center in Bochum, Germany, in collaboration with the European Bioinformatics Institute in Hinxton, UK, and other collaborators.

Professor Helmut E. Meyer, Director of the HUPO Brain Proteome Project, pointed out: "In particular, the new features of ProteinScape allow us to store, handle and analyze the huge amount of data in a very effective way." He will present BPP data during the Congress.

With Bruker Daltonics' addition of the mzData standard format to ProteinScape, mass spectrometry data comparison, exchange and verification have been facilitated. The mzData format was established as a standard data exchange format by the HUPO PSI. Research scientists get extraordinary flexibility in sharing these data more easily, greatly accelerating the process of extracting knowledge from the experimental data.

"The use of a sophisticated bioinformatics database system is a requirement for the successful management of the vast amount of heterogeneous data resulting from the great variety of workflow approaches used in proteomics today," said Professor Herbert Thiele, Director of Bioinformatics at Bruker Daltonics. "The HUPO BPP reprocessing effort clearly indicates the need for advanced algorithms for data evaluation and validation. More quality results generate more confidence and produce much more relevant knowledge."

Bruker Daltonics scientists will make various presentations at the HUPO World Congress. For information about the Congress, please see www.hupo2005.com.

ProteinScape is a co-development of Bruker Daltonics and Protagen AG of Dortmund, Germany, and is distributed exclusively by Bruker Daltonics.

ABOUT BRUKER BIOSCIENCES

Bruker BioSciences Corporation (NASDAQ: BRKR), headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker AXS Inc. and Bruker Daltonics Inc. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. For more information, please visit www.bdal.com and www.bruker-biosciences.com

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2004, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements.